As patients with heart failure (HF) and concomitant diabetes carry a poor prognosis, this post-hoc subgroup analysis aimed to compare the outcomes of patients with and without diabetes randomized in the Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT) study. 
Introduction
Patients with diabetes mellitus have an elevated risk for cardiac events, including the development of heart failure (HF). Conversely, the prognosis of patients with symptomatic HF and concomitant diabetes is dire, with both morbidity and mortality well in excess of that observed in patients without diabetes.
1 -3 Cardiac resynchronization therapy (CRT) reduces morbidity and mortality in patients with symptomatic HF with reduced ejection fraction and a wide QRS complex, 4 -7 and has become standard of care in the treatment of such patients. 8 Patients with diabetes have been demonstrated to derive at least a similar benefit from CRT than patients without diabetes based on several subanalyses of large randomized clinical trials. 9 -12 In the same way, a substantial benefit of CRT was observed for diabetic patients in real world registries.
13,14
Based on the observation that a substantial proportion of HF patients presents with a narrow QRS complex, 15 the Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT) trial 16 was conducted to assess the effect of CRT in patients with a QRS duration <130 ms who present with echocardiographic evidence of left ventricular dyssynchrony. The trial was terminated early because of futility, and demonstrated a relative increase in all-cause mortality of 81% with CRT in this patient population. 16 Evidence on the effect of CRT in HF patients with diabetes and a narrow QRS complex is scarce. While a more beneficial response appears possible as extrapolated from data on diabetic patients with a wide QRS complex, 11, 17 patients with diabetes are known to be more susceptible to arrhythmias and may thus be at higher risk in the context of a narrow QRS complex and biventricular pacing. 18 This post-hoc subgroup analysis was therefore performed to assess the efficacy and safety of CRT in patients with and without diabetes randomized in EchoCRT.
Methods

Study design and conduct
The EchoCRT trial was an investigator-initiated, multicentre, international, randomized clinical trial. The results of the main trial, including the methodology, have been reported previously. 16 Patients were eligible if they were on optimized medical HF therapy, had a standard indication for an implantable cardioverter-defibrillator (ICD), were suffering from symptomatic HF [New York Heart Association (NYHA) class III or IV], had a left ventricular ejection fraction (EF) ≤35%, a QRS duration of <130 ms, a left ventricular end-diastolic diameter (LVEDD) of ≥55 mm, and echocardiographic evidence of left ventricular dyssynchrony, as defined previously. 16 After implantation of a Biotronik Lumax HF-T CRT-D system, patients were randomly assigned in a 1:1 ratio to have cardiac resynchronization turned on (CRT = ON group) or off (CRT = OFF control group). While physicians involved in the device implantation and follow-up were aware of the study-group assignments, HF physicians, patients, and study personnel completing the follow-up assessments were not. The trial was designed by the executive committee and was sponsored by Biotronik (Berlin, Germany) with support for echocardiographic training and software provided by GE Healthcare (Buckinghamshire, United Kingdom). Diagnosis of diabetes was made at the discretion of the local study site investigators at enrolment into the trial. In cases where diagnosis of diabetes
was unclear (n = 13), diagnosis was made by the central study team according to available medical reports and concomitant medication.
Endpoints
The primary combined efficacy outcome consisted of the combination of death from any cause or first hospitalization for worsening HF. 16 The pre-specified secondary outcomes included time to first hospitalization for worsening HF, all-cause mortality, cardiovascular mortality, and cardiovascular hospitalization. 16 The primary safety outcome was freedom from CRT-D related complications at 6 months in the implanted population.
Statistical analysis
All study results were independently analysed at the Robertson Centre for Biostatistics at the University of Glasgow. All analyses were performed by intention-to-treat. Baseline characteristics were compared with the use of chi-square (or Fisher's exact) test and two-sample t-tests for categorical and continuous variables, respectively. Hazard ratios (HRs) for CRT = OFF and CRT = ON [with 95% confidence interval (CI)] were calculated with the Cox proportional hazards models for patients with vs. without diabetes, stratified for country. In addition, a multivariable Cox proportional hazards model was performed to account for differences across randomized treatment groups in baseline characteristics between patients with and without diabetes (age, gender, sitting systolic blood pressure, body mass index, ischaemic cardiomyopathy, history of coronary artery bypass graft and chronic kidney disease). Interactions between patients with and without diabetes (CRT = ON and CRT = OFF) were tested for in Cox models that included diabetes and treatment main effects and interaction terms. Time to event curves were estimated with the use of the Kaplan-Meier method. All tests were two-sided and a P-value <0.05 was considered significant.
Results
Baseline characteristics
Patient characteristics at trial entry are shown in Table 1 . Out of 809 randomized patients, 328 (40.5%) had a diagnosis of diabetes at baseline. In three patients, the status of diabetes could not be definitively assessed. Of the 328 patients with diabetes at baseline, 172 (52.4%) were randomized to CRT = ON and 156 (47.6%) to CRT = OFF. Of the 478 patients without diabetes, 230 (48.1%) were randomized to CRT = ON and 248 (51.9%) to CRT = OFF. Baseline characteristics by group allocation and diabetes status are shown in the Supplementary material online, Table S1 . There was no significant difference in group allocation to CRT = ON between patients with vs. without diabetes (P = 0.228). Patients with diabetes were older, had a higher average body mass index, more frequently had hypertension, chronic kidney disease, or thyroid disease, and more frequently had underlying ischaemic cardiomyopathy and previous coronary artery bypass grafting. They achieved a shorter walking distance, reported worse HF-related quality of life and were more frequently treated with diuretics, nitrates, statins, and aspirin. CRT-OFF in patients without diabetes compared with patients with diabetes (P for interaction 0.029). The interaction by diabetes status for the primary endpoint remained borderline significant (P for interaction 0.063) after adjustment for baseline parameters ( Figure 3 ). An exploratory post-hoc analysis revealed that patients with non-ischaemic cardiomyopathy were the main driver of this effect. Of the 374 patients with non-ischaemic cardiomyopathy, 125 had a diagnosis of diabetes of which 64 (51.2%) were randomized to CRT = ON. A significantly reduced risk to reach the primary efficacy endpoint for CRT = ON vs. CRT-OFF was observed in patients with (25.01% vs. 32.8%; HR 0.27, 95% CI 0.11-0.65; P = 0.005) compared with those without diabetes (29.2% vs. 17.1%; HR 1.79, 95% CI 1.03-3.11; P = 0.04) in patients with non-ischaemic cardiomyopathy after multivariate adjustment (P for interaction 0.005). In contrast, no difference in events was observed for CRT = ON vs. CRT = OFF in ischaemic cardiomyopathy (HR 1.09, 95% CI 0.67- 1.78 ; P = 0.72 vs. HR 1.10, 95% CI 0.62-1.97; P = 0.74) for diabetic vs. non-diabetic patients, respectively, after multivariate adjustment (P for interaction 0.96).
There was no treatment interaction for all-cause mortality (Figure 1b) , as well as HF and cardiovascular mortality in patients with vs. without diabetes, both unadjusted ( Figure 2 ) and after adjustment for baseline differences (Figure 3) . Indeed, in the fully adjusted analysis, the HR for all-cause mortality in the CRT = ON vs. CRT = OFF group was 1.58 (95% CI 0.78- 3.20) in patients with diabetes and 1.60 (95% CI 0.77-3.32) in patients without diabetes (P for interaction 0.98).
Discussion
The current subgroup analysis of EchoCRT reveals three important key findings. First, in this population of HF patients with a narrow QRS complex and echocardiographic signs of dyssynchrony, patients with diabetes show less evidence of harm by CRT than patients without diabetes. Second, these differences in the primary outcome are primarily driven by differences in HF hospitalizations. Third, although patients with diabetes had an overall higher morbidity and mortality, no significant differences in CRT-D-or implant-related complications were seen between patients with or without diabetes. The presence of diabetes poses a challenge in the everyday treatment of patients with HF, with a worse prognosis observed in a multitude of clinical trials and registries.
1 -3 Conversely, patients with diabetes enrolled in the pivotal CRT trials generally fared worse than those without diabetes. In CARE-HF, the risk of all-cause mortality was increased by 30% in patients with compared with those without diabetes by the end of the extension period. 9 In MADIT-CRT 11 patients with diabetes more frequently reached Hazard ratio (HR) and 95% confidence interval (CI) adjusted for country, age, gender, sitting systolic blood pressure, body mass index, ischaemic cardiomyopathy, history of coronary artery bypass graft and history of chronic kidney disease (P-value from Wald test). CRT = ON, CRT turned on; CRT = OFF, CRT turned off (control). WHF, worsening heart failure; int., interaction.
the primary endpoint compared with those without diabetes (26.6% vs. 18%). In COMPANION, 10 a numerically increased risk for mortality and/or HF hospitalization was observed in patients with diabetes, which was not significant after multivariate adjustment. Our data demonstrating an increased risk for both HF hospitalization and all-cause mortality in diabetic patients are hence in line with the results from previous landmark trials in diabetic patients receiving CRT.
In those same trials, patients with diabetes derived at least a similar if not greater benefit from CRT than those without diabetes. In CARE-HF, 9 patients randomized to CRT pacemaker (CRT-P) vs. optimal medical therapy had a similar reduction in all endpoints independent of concomitant diabetes. In COMPANION, 10 a reduction of all major morbidity and/or mortality endpoints was observed in the combined cohort of diabetic patients receiving CRT-P or CRT-D compared with diabetic patients on optimal medical therapy. In MADIT-CRT, 11 a consistent effect of CRT-D as compared to ICD therapy was observed in patients with and without diabetes, with a suggestion of an earlier and greater benefit from CRT-D in patients with diabetes. Importantly, in the latter trial, the benefit of CRT appears greater in diabetic patients with non-ischaemic cardiomyopathy than in those with ischaemic cardiomyopathy, although there was no statistically significant interaction (HR 0.30 vs. 0.59; P for interaction 0.10). 19 This observation led us to further post-hoc dissection of the effect of CRT in patients with diabetes and non-ischaemic cardiomyopathy. In line with MADIT-CRT, 11 CRT was associated with a 76% reduced risk for the primary composite endpoint in patients with non-ischaemic cardiomyopathy and coexisting diabetes in the present study, which . is almost identical to the 70% relative risk reduction observed in MADIT-CRT. 19 In contrast, a 79% increased relative risk for the primary outcome with CRT was observed in patients with non-ischaemic cardiomyopathy without diabetes.
The mechanism underlying this differential effect is unclear at present, but may be related to a different pathophysiology of diabetic cardiomyopathy in patients with vs. without clinically apparent coronary artery disease. Indeed, patients with diabetes may develop overt HF in the absence of coronary artery disease, 20 which may be related to a variety of pathophysiological changes including metabolic disturbances, myocardial fibrosis, small vessel disease, cardiac autonomic neuropathy, and insulin resistance. 21 In the Framingham Heart Study cohort, patients with diabetes had increased left ventricular mass and wall thickness on echocardiography, which remains significant even after adjusting for confounding factors. 22 Whether and how these factors may be involved in the differential effect observed in EchoCRT currently remains elusive and will require further study. The premature termination of the trial as well as the absolute low number of events precludes further meaningful sub-subanalysis within the non-ischaemic diabetic patient group, including investigation of individuals who potentially benefit more from CRT, such as women.
The trend towards less harm in the primary composite endpoint in diabetic patients randomized to CRT = ON was primarily driven by differences in HF hospitalizations. No difference in all-cause mortality for CRT = ON vs. CRT-OFF was observed among patients with and without diabetes. This contrasts with MADIT-CRT where CRT reduced all-cause mortality to a significantly higher extent in insulin-treated diabetic patients compared to orally treated diabetic patients and patients without diabetes in a recent subanalysis of the trial.
11,17
The reasons for the differential effect of CRT between diabetic patients with a narrow and a wide QRS complex are unclear. On one hand, several mechanisms for a worse outcome in diabetic patients receiving CRT may be conceivable, such as myocardial fibrosis, microvascular dysfunction, lipid accumulation, altered autonomic tone, or side-effects of anti-glycaemic drugshypoglycaemia in particular. 23 -25 Combined, these phenomena may make patients with diabetes more prone to any potential pro-arrhythmogenic effect of CRT in the context of a narrow QRS complex. On the other hand, CRT has been shown to improve the metabolomic profile of HF patients and CRT-mediated restoration of glucose metabolism may be especially advantageous for insulin-treated diabetic patients. 26, 27 Finally, based on a small study, patients with diabetes may have more pronounced echocardiographic dyssynchrony-despite similar QRS duration-than non-diabetic patients, making them potentially more amendable to cardiac resynchronization. 28 However, no significant differences in the extent of echocardiographic dyssynchrony were found at baseline or at 6 months in patients with compared with those without diabetes in EchoCRT, 29 although the dyssynchrony entry criteria may have created a bias in this regard. In addition, none of these observations readily explain the different response between EchoCRT and MADIT-CRT patients, and further investigations are required to elucidate the underlying mechanisms involved.
Limitations
Any subgroup analysis, including the current investigation of patients with diabetes should, by definition, be interpreted as hypothesis generating. According to the current 2016 European Society of Cardiology HF guidelines, CRT is not recommended for patients with a QRS duration <130 ms, independent of the presence or absence of diabetes. 30 As EchoCRT demonstrated an excess of mortality of patients randomized to CRT, the trial was stopped prematurely, thus reducing the statistical power of any subgroup analysis. As such, for some analyses event rates were relatively low, particularly when assessing the sub-subgroup of non-ischaemic vs. ischaemic cardiomyopathy. The trial excluded patients with atrial fibrillation and advanced renal insufficiency, hence selection bias in the diabetic patients included in the study cannot be excluded. Glucose and glycated haemoglobin (HbA 1c ) levels were not available at the time of diagnosis or during follow-up. As a result, misclassification may have occurred in some patients. Furthermore, no sub-subgroup analyses could be performed according to glycemic control (e.g. low vs. high HbA 1c ). In addition, information on the type of diabetes was not available. Given the age and characteristics of the study population, it is very likely that the majority of patients had a diagnosis of type 2 diabetes. Finally, detailed information on the anti-diabetic treatments were not available and thus no analyses by oral and non-oral anti-diabetic medications (i.e. insulin use) could be performed.
. 
Conclusion
In the present subgroup analysis of EchoCRT in patients with HF and a narrow QRS complex, a signal for less harm of CRT was found in patients with compared with those without diabetes. This effect was mainly observed in patients with non-ischaemic cardiomyopathy and was driven by differences in HF hospitalizations without significant differences in mortality. These results, together with the consistent data from the other large CRT trials, may help clinical decision making in the 'grey zone' of CRT indications. Further studies are required to analyse the underlying mechanisms of these results in order to maximize the benefit of CRT in this difficult to treat patient population.
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